Robert LeBoyer
Stock Analyst at Noble Capital Markets
(2.01)
# 2,812
Out of 4,784 analysts
18
Total ratings
37.5%
Success rate
7.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $20.17 | +247.05% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $6.26 | +107.67% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $6 → $10 | $1.11 | +800.90% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $6 | $0.61 | +877.20% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $18.46 | +225.03% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $3.35 | +198.51% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $1.62 | +764.20% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $0.49 | +1,526.35% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $1.16 | +10,244.83% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $13.43 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $8.72 | +37.61% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $825,000 | $1.30 | +63,461,438.46% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.35 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $5.53 | +171.25% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $20.17
Upside: +247.05%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $6.26
Upside: +107.67%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6 → $10
Current: $1.11
Upside: +800.90%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $6
Current: $0.61
Upside: +877.20%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $18.46
Upside: +225.03%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $3.35
Upside: +198.51%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.62
Upside: +764.20%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $0.49
Upside: +1,526.35%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $1.16
Upside: +10,244.83%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $13.43
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $8.72
Upside: +37.61%
Aug 24, 2020
Initiates: Buy
Price Target: $825,000
Current: $1.30
Upside: +63,461,438.46%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $17.35
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $5.53
Upside: +171.25%